Magdalena Bodera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Magdalena Bodera has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Radosław Szydłowski
Medical University of Silesia, Katowice, Poland
19 shared publications - Hanna Porwolik
Medical University of Silesia, Katowice, Poland
16 shared publications - Anna Kaźmierska
Medical University of Silesia, Katowice, Poland
13 shared publications - Agata Porwolik
Professor Zbigniew Religa Student Scientific Association at the Department of Biophysics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Jordana 19, 41-808 Zabrze, Poland
11 shared publications - Anna Hamerla
Professor Zbigniew Religa Student Scientific Association at the Department of Biophysics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland
7 shared publications - Dominik Bylica
Zespół Szpitali Miejskich w Chorzowie, Chorzów, Poland
7 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
CANCER PAIN IN PALLIATIVE CARE: ASSESSMENT, MONITORING, AND THE ROLE OF NURSING
Cancer is one of the leading causes of death, following cardiovascular diseases. Despite significant advances in medicine, cancer incidence continues to rise, with the number of affected individuals having doubled over the past decades. Pain is the most common symptom experienced during the course of cancer. On average, approximately half of patients with cancer, at various stages of the disease, suffer from pain. According to the concept proposed by Cicely Saunders, founder of St Christopher’s Hospice in London, cancer pain is a multidimensional and overwhelming experience referred to as “total pain” which includes physical, psychological, social, and spiritual components. The aim of this study is to present the issue of pain in the course of cancer, to define appropriate nursing management strategies for the assessment and monitoring of this symptom, and to provide a descriptive analysis of current knowledge on pain and its treatment. This paper is based on a review of the relevant literature, including textbooks, scientific articles, and current legal regulations. It consists of three chapters addressing palliative care, the characteristics of cancer pain, and principles of nursing management in its assessment and control.
- 22 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open AccessCANCER PAIN IN PALLIATIVE CARE: ASSESSMENT, MONITORING, AND THE ROLE OF NURSING
Cancer is one of the leading causes of death, following cardiovascular diseases. Despite significant advances in medicine, cancer incidence continues to rise, with the number of affected individuals having doubled over the past decades. Pain is the most common symptom experienced during the course of cancer. On average, approximately half of patients with cancer, at various stages of the disease, suffer from pain. According to the concept proposed by Cicely Saunders, founder of St Christopher’s Hospice in London, cancer pain is a multidimensional and overwhelming experience referred to as “total pain” which includes physical, psychological, social, and spiritual components. The aim of this study is to present the issue of pain in the course of cancer, to define appropriate nursing management strategies for the assessment and monitoring of this symptom, and to provide a descriptive analysis of current knowledge on pain and its treatment. This paper is based on a review of the relevant literature, including textbooks, scientific articles, and current legal regulations. It consists of three chapters addressing palliative care, the characteristics of cancer pain, and principles of nursing management in its assessment and control.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
IODINE SUPPLEMENTATION IN CHILDHOOD: PREVENTING THYROID DISORDERS IN THE ERA OF PRECISION MEDICINE
Iodine deficiency disorders (IDDs) are a group of conditions that have been identified as one of the most preventable but persisting important causes of irreversible neuro-cognitive impairment among paediatric populations across the world (Bertinato, 2021; Feei & Brough, 2025; Zimmermann & Andersson, 2021). Existing universal supplementation programmes are showing to be inadequate as they do not accommodate the new regional deficiencies and the concomitant risk of iodine excess (Kalarani & Veerabathiran, 2022; Seetharaman et al., 2024). This paper proposes a paradigm shift in paediatric endocrinology to precision medicine, in which the iodine interventions are tailored to each child. Wearable biosensors, which continuously monitor physiological and biochemical parameters, complex mobile-health applications which can track dietary intake in real-time, support adherence, and education, as well as comprehensive telehealth platforms which allow remote care (Fernández-Luque et al., 2021; Foster et al., 2022; Kim et al., 2023; Magsayo & Khatami, 2025; Majeed‐Ariss et al., 2015; Mercuri et al., 2021; Rashid, 2024; Zhou et al., 2024). Integration of advanced biomarkers and multi-omics data (genomics, proteomics, metabolomics and microbiomics) - integrated with AI/ML algorithms - will help to dynamically predict risk, implement early intervention strategies and design protocols for the supplementation of these individuals (Bidlingmaier et al., 2022; Dhanka et al., 2025; Giorgini et al., 2023; Lu et al., 2025; Mehta et al., 2025). By combining technology with personalised care, this strategy promises to optimise iodine nutrition, protect neurodevelopment and enhance the long term health outcomes of all children (Delange, 2007; Milanesi & Brent, 2016; Untoro et al., 2007).
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessIODINE SUPPLEMENTATION IN CHILDHOOD: PREVENTING THYROID DISORDERS IN THE ERA OF PRECISION MEDICINE
Iodine deficiency disorders (IDDs) are a group of conditions that have been identified as one of the most preventable but persisting important causes of irreversible neuro-cognitive impairment among paediatric populations across the world (Bertinato, 2021; Feei & Brough, 2025; Zimmermann & Andersson, 2021). Existing universal supplementation programmes are showing to be inadequate as they do not accommodate the new regional deficiencies and the concomitant risk of iodine excess (Kalarani & Veerabathiran, 2022; Seetharaman et al., 2024). This paper proposes a paradigm shift in paediatric endocrinology to precision medicine, in which the iodine interventions are tailored to each child. Wearable biosensors, which continuously monitor physiological and biochemical parameters, complex mobile-health applications which can track dietary intake in real-time, support adherence, and education, as well as comprehensive telehealth platforms which allow remote care (Fernández-Luque et al., 2021; Foster et al., 2022; Kim et al., 2023; Magsayo & Khatami, 2025; Majeed‐Ariss et al., 2015; Mercuri et al., 2021; Rashid, 2024; Zhou et al., 2024). Integration of advanced biomarkers and multi-omics data (genomics, proteomics, metabolomics and microbiomics) - integrated with AI/ML algorithms - will help to dynamically predict risk, implement early intervention strategies and design protocols for the supplementation of these individuals (Bidlingmaier et al., 2022; Dhanka et al., 2025; Giorgini et al., 2023; Lu et al., 2025; Mehta et al., 2025). By combining technology with personalised care, this strategy promises to optimise iodine nutrition, protect neurodevelopment and enhance the long term health outcomes of all children (Delange, 2007; Milanesi & Brent, 2016; Untoro et al., 2007).
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
COMPLICATIONS OF TRANSCATHETER AORTIC VALVE IMPLANTATION
Transcatheter aortic valve implantation (TAVI) has become an established and widely adopted treatment for patients with severe aortic stenosis across all surgical risk categories. Continuous technological progress, refinements in device design, and increasing operator experience have substantially improved procedural safety and expanded indications from inoperable and high-risk patients to those at intermediate and low surgical risk. Nevertheless, despite these advancements, TAVI remains associated with a broad spectrum of complications that may adversely affect both short- and long-term outcomes. This review provides a comprehensive overview of the most clinically significant complications following TAVI, including vascular, valvular, neurological, renal, bleeding, infectious, and conduction-related events. Particular attention is given to the underlying pathophysiological mechanisms, patient- and procedure-related risk factors, and contemporary prevention and management strategies. Although the incidence of major vascular complications has decreased with the introduction of lower-profile delivery systems, these events remain clinically relevant, particularly in elderly patients and those with complex vascular anatomy. Conduction disturbances frequently require permanent pacemaker implantation, while stroke and silent cerebral embolization continue to represent major neurological concerns. Acute kidney injury and major bleeding significantly contribute to morbidity and mortality, and prosthetic valve endocarditis, although rare, carries a particularly poor prognosis. A thorough understanding of the mechanisms and predictors of post-TAVI complications is essential for optimizing patient selection, procedural planning, and post-procedural management. Ongoing innovations in device technology and procedural techniques remain fundamental to further improving clinical outcomes and minimizing procedural risk.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessCOMPLICATIONS OF TRANSCATHETER AORTIC VALVE IMPLANTATION
Transcatheter aortic valve implantation (TAVI) has become an established and widely adopted treatment for patients with severe aortic stenosis across all surgical risk categories. Continuous technological progress, refinements in device design, and increasing operator experience have substantially improved procedural safety and expanded indications from inoperable and high-risk patients to those at intermediate and low surgical risk. Nevertheless, despite these advancements, TAVI remains associated with a broad spectrum of complications that may adversely affect both short- and long-term outcomes. This review provides a comprehensive overview of the most clinically significant complications following TAVI, including vascular, valvular, neurological, renal, bleeding, infectious, and conduction-related events. Particular attention is given to the underlying pathophysiological mechanisms, patient- and procedure-related risk factors, and contemporary prevention and management strategies. Although the incidence of major vascular complications has decreased with the introduction of lower-profile delivery systems, these events remain clinically relevant, particularly in elderly patients and those with complex vascular anatomy. Conduction disturbances frequently require permanent pacemaker implantation, while stroke and silent cerebral embolization continue to represent major neurological concerns. Acute kidney injury and major bleeding significantly contribute to morbidity and mortality, and prosthetic valve endocarditis, although rare, carries a particularly poor prognosis. A thorough understanding of the mechanisms and predictors of post-TAVI complications is essential for optimizing patient selection, procedural planning, and post-procedural management. Ongoing innovations in device technology and procedural techniques remain fundamental to further improving clinical outcomes and minimizing procedural risk.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
MODERN GLP-1 BASED PHARMACOTHERAPY FOR SEVERE ADOLESCENT OBESITY: CLINICAL PROMISE, SAFETY CONCERNS, AND ETHICAL CHALLENGES
Childhood obesity is an emerging worldwide health crisis, which has far-reaching harmful impacts on the health and development of affected adolescents (Hesketh et al., 2024; Li et al., 2024; Marcus et al., 2022). Innovative therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown great promise as pharmacological intervention, with substantive clinical benefit to the population. This review provides a detailed synthesis of GLP-1RAs from the perspectives of their pharmacological mechanisms, clinical potential in adolescents, safety profiles and associated ethical and social considerations. The pharmacological rationale for GLP-1RAs is due to their ability to mimic the effect of endogenous GLP-1, a hormone which plays an important role in maintaining glucose homeostasis and in regulating appetite (Moiz et al., 2025; Muzurović et al., 2022). These agents promote glucose-dependent insulin secretion, reduce glucagon release and also slow gastric emptying, thereby attenuating glycaemic excursions after a meal and promoting satiety (Alharbi, 2025; Drucker, 2021; Shah & Vella, 2014). Importantly, GLP-1RAs also activate receptors in the central nervous system to reduce hunger and food intake, which result in weight loss of significant and sustained magnitude (Dailey & Moran, 2013; Hayes, 2012; Moiz et al., 2025). This multifaceted mechanism is the basis of their efficacy to treat both type 2 diabetes and obesity. Within the adolescent age group, GLP-1RAs have shown significant clinical potential especially with liraglutide and semaglutide.Liraglutide, approved for people aged 12-17 years, has led to better body mass index (BMI) z-score and clinically significant reduction in weight compared with placebo (Berman et al., 2023; Jensterle & Janež, 2021). Semaglutide, which is approved for adolescents 12+ years, continues to push the efficacy bar and confirmatory trials have reported mean BMI reductions of over 16% with a high prevalence of participants achieving significant weight loss (Weghuber, Barrett, et al., 2023; Weghuber, Kelly, et al., 2023). Beyond reducing weight, GLP-1RAs improve key metabolic markers - triglycerides, total cholesterol, HbA1c and systolic blood pressure - which reduces the risk of cardiovascular and type 2 diabetes in the long term (Silvia et al., 2021; Weghuber, Barrett, et al., 2023; Weghuber, Kelly, et al., 2023). Moreover, these medications improve weight-related quality of life, especially the physical comfort, which addresses the psychological burden of obesity in youth (Weghuber, Barrett, et al., 2023; Weghuber, Kelly, et al., 2023). Despite their efficacy, GLP-1RAs are a unique category of pharmacologic agents with regard to safety profile that requires close scrutiny. Frequently encountered adverse events are gastrointestinal in nature - nausea, vomiting, diarrhoea and constipation - generally being mild, transient and amenable to dose titration (Santos & Castro, 2025; Silvia et al., 2021). More serious issues include proven risks of cholelithiasis and acute pancreatitis, as seen in some trials (Weghuber et al., 2022; Woronow et al., 2022). A black box warning (defined by FDA) is used to alert clinicians to the potential risk of thyroid C-cells tumours, such as medullary thyroid carcinoma, based on rodent studies, and therefore require contraindication in certain clinical situations (Bezin et al., 2022; Kelly & Sipos, 2024; Pasternak et al., 2024).Long-term data on the effect of GLP-1RA on adolescent growth, pubertal development and neuropsychiatric outcomes (including suicidal ideation) are still sparse and the need for continued, rigorous surveillance (Bartkoski et al., 2025; Cooper et al., 2023). Ethical and societal considerations are very important when incorporating GLP-1RAs into the care of adolescents. Challenges include the need for truly informed consent, and respect for adolescent autonomy, in particular because of the chronic nature of therapy (Turhal & Bağlam, 2025; Viner et al., 2020). Dramatic increases in cost and poor insurance coverage create important equity issues, which may serve to exacerbate health disparities (Berman et al., 2023; Wright et al., 2023). Societal stigma against obesity and the potential for reinforcing a "weight-normative" paradigm or misuse for cosmetic purposes also need to be watched out for (Button et al., 2025; Cominato et al., 2021; Floegel‐Shetty, 2023). A holistic approach that goes beyond simply reducing weight to include but is not limited to metabolic health, psychological wellbeing, and quality of life is crucial to ethical and effective practice. In conclusion, GLP-1RAs have been shown to be a transformational approach in the management of severe obesity in adolescents, but their introduction into the clinic will need to be accompanied by a commitment to long-term safety studies and equitable and patient-centred care.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessMODERN GLP-1 BASED PHARMACOTHERAPY FOR SEVERE ADOLESCENT OBESITY: CLINICAL PROMISE, SAFETY CONCERNS, AND ETHICAL CHALLENGES
Childhood obesity is an emerging worldwide health crisis, which has far-reaching harmful impacts on the health and development of affected adolescents (Hesketh et al., 2024; Li et al., 2024; Marcus et al., 2022). Innovative therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown great promise as pharmacological intervention, with substantive clinical benefit to the population. This review provides a detailed synthesis of GLP-1RAs from the perspectives of their pharmacological mechanisms, clinical potential in adolescents, safety profiles and associated ethical and social considerations. The pharmacological rationale for GLP-1RAs is due to their ability to mimic the effect of endogenous GLP-1, a hormone which plays an important role in maintaining glucose homeostasis and in regulating appetite (Moiz et al., 2025; Muzurović et al., 2022). These agents promote glucose-dependent insulin secretion, reduce glucagon release and also slow gastric emptying, thereby attenuating glycaemic excursions after a meal and promoting satiety (Alharbi, 2025; Drucker, 2021; Shah & Vella, 2014). Importantly, GLP-1RAs also activate receptors in the central nervous system to reduce hunger and food intake, which result in weight loss of significant and sustained magnitude (Dailey & Moran, 2013; Hayes, 2012; Moiz et al., 2025). This multifaceted mechanism is the basis of their efficacy to treat both type 2 diabetes and obesity. Within the adolescent age group, GLP-1RAs have shown significant clinical potential especially with liraglutide and semaglutide.Liraglutide, approved for people aged 12-17 years, has led to better body mass index (BMI) z-score and clinically significant reduction in weight compared with placebo (Berman et al., 2023; Jensterle & Janež, 2021). Semaglutide, which is approved for adolescents 12+ years, continues to push the efficacy bar and confirmatory trials have reported mean BMI reductions of over 16% with a high prevalence of participants achieving significant weight loss (Weghuber, Barrett, et al., 2023; Weghuber, Kelly, et al., 2023). Beyond reducing weight, GLP-1RAs improve key metabolic markers - triglycerides, total cholesterol, HbA1c and systolic blood pressure - which reduces the risk of cardiovascular and type 2 diabetes in the long term (Silvia et al., 2021; Weghuber, Barrett, et al., 2023; Weghuber, Kelly, et al., 2023). Moreover, these medications improve weight-related quality of life, especially the physical comfort, which addresses the psychological burden of obesity in youth (Weghuber, Barrett, et al., 2023; Weghuber, Kelly, et al., 2023). Despite their efficacy, GLP-1RAs are a unique category of pharmacologic agents with regard to safety profile that requires close scrutiny. Frequently encountered adverse events are gastrointestinal in nature - nausea, vomiting, diarrhoea and constipation - generally being mild, transient and amenable to dose titration (Santos & Castro, 2025; Silvia et al., 2021). More serious issues include proven risks of cholelithiasis and acute pancreatitis, as seen in some trials (Weghuber et al., 2022; Woronow et al., 2022). A black box warning (defined by FDA) is used to alert clinicians to the potential risk of thyroid C-cells tumours, such as medullary thyroid carcinoma, based on rodent studies, and therefore require contraindication in certain clinical situations (Bezin et al., 2022; Kelly & Sipos, 2024; Pasternak et al., 2024).Long-term data on the effect of GLP-1RA on adolescent growth, pubertal development and neuropsychiatric outcomes (including suicidal ideation) are still sparse and the need for continued, rigorous surveillance (Bartkoski et al., 2025; Cooper et al., 2023). Ethical and societal considerations are very important when incorporating GLP-1RAs into the care of adolescents. Challenges include the need for truly informed consent, and respect for adolescent autonomy, in particular because of the chronic nature of therapy (Turhal & Bağlam, 2025; Viner et al., 2020). Dramatic increases in cost and poor insurance coverage create important equity issues, which may serve to exacerbate health disparities (Berman et al., 2023; Wright et al., 2023). Societal stigma against obesity and the potential for reinforcing a "weight-normative" paradigm or misuse for cosmetic purposes also need to be watched out for (Button et al., 2025; Cominato et al., 2021; Floegel‐Shetty, 2023). A holistic approach that goes beyond simply reducing weight to include but is not limited to metabolic health, psychological wellbeing, and quality of life is crucial to ethical and effective practice. In conclusion, GLP-1RAs have been shown to be a transformational approach in the management of severe obesity in adolescents, but their introduction into the clinic will need to be accompanied by a commitment to long-term safety studies and equitable and patient-centred care.
- Open Access
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
THE EFFECT OF EXCESSIVE SMARTPHONE USE ON MENTAL WELLBEING, SLEEP QUALITY AND ACTIVE LIFESTYLE BEHAVIOURS
Introduction: Mobile phone addiction has become a very common phenomenon among young people. It leads to a number of negative consequences for their health, both physical and mental. The aim of this paper is to present the most important consequences of excessive phone use in terms of mental health, such as depression, anxiety and feelings of loneliness. Issues such as the impact of phone addiction on sleep disorders, orthorexia and eating behaviour are also discussed. The paper highlights that excessive use of mobile devices can significantly affect the quality of life of young people, contributing to emotional disturbances and reduced psychological well-being. Conclusions point to the need for further research and educational activities to reduce the negative impact of this phenomenon. Methodology: For this work, we conducted a search in the PubMed and Google Scholar databases using the keywords: "phone addiction," " health," " lifestyle," " mental wellbeing" followed by an analysis of the selected materials. Aim of the study: The aim of this work is to analyse the impact of smartphone addiction on young people's mental health, with a focus on aspects such as depression, anxiety, sleep disorders, orthorexia, social relationships and feelings of loneliness. Conclusion: Excessive use of mobile devices can have a significant impact on the quality of life of young people, contributing to emotional, sleep and eating disorders. Preventive measures are advisable, including education on sleep hygiene, limiting the time spent in front of screens before bedtime and promoting healthy lifestyles among young people and students.
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Open AccessTHE EFFECT OF EXCESSIVE SMARTPHONE USE ON MENTAL WELLBEING, SLEEP QUALITY AND ACTIVE LIFESTYLE BEHAVIOURS
Introduction: Mobile phone addiction has become a very common phenomenon among young people. It leads to a number of negative consequences for their health, both physical and mental. The aim of this paper is to present the most important consequences of excessive phone use in terms of mental health, such as depression, anxiety and feelings of loneliness. Issues such as the impact of phone addiction on sleep disorders, orthorexia and eating behaviour are also discussed. The paper highlights that excessive use of mobile devices can significantly affect the quality of life of young people, contributing to emotional disturbances and reduced psychological well-being. Conclusions point to the need for further research and educational activities to reduce the negative impact of this phenomenon. Methodology: For this work, we conducted a search in the PubMed and Google Scholar databases using the keywords: "phone addiction," " health," " lifestyle," " mental wellbeing" followed by an analysis of the selected materials. Aim of the study: The aim of this work is to analyse the impact of smartphone addiction on young people's mental health, with a focus on aspects such as depression, anxiety, sleep disorders, orthorexia, social relationships and feelings of loneliness. Conclusion: Excessive use of mobile devices can have a significant impact on the quality of life of young people, contributing to emotional, sleep and eating disorders. Preventive measures are advisable, including education on sleep hygiene, limiting the time spent in front of screens before bedtime and promoting healthy lifestyles among young people and students.
- Open Access
- 4 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
VERICIGUAT: MODERN THERAPY FOR THE TREATMENT OF CHRONIC HEART FAILURE
Vericiguat is the first oral soluble guanylate cyclase (sGC) stimulator developed to reduce the risk of cardiovascular death and heart failure–related hospitalizations in patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF). sGC dysfunction, resulting in impaired synthesis of cyclic guanosine monophosphate (cGMP), may play a keyrole in the pathophysiology of heart failure by affecting myocardial function, vascular tone, and peripheral tissue perfusion. Vericiguat exerts its therapeutic effect by enhancing intracellular cGMP levels, leading to improved cardiac function and vasodilation. Consequently, the drug represents a promising treatment option for patients with HFrEF, particularly those with recent decompensation, requiring intravenous diuretic therapy, or at high risk for rehospitalization due to disease exacerbation. Clinical efficacy of vericiguat was demonstrated in the VICTORIA trial, which enrolled 6,857 patients with HFrEF following recent decompensation. After a median follow-up of 10.8 months, treatment with vericiguat significantly reduced the risk of the composite endpoint of cardiovascular death or heart failure related hospitalization compared with placebo. Patients with more advanced disease also exhibited reductions in NT-proBNP levels, suggesting a potential biomarker of therapeutic response. Vericiguat is generally well tolerated. The most commonly reported adverse events are hypotension and syncope. The drug can be safely administered to patients with mild to moderate renal or hepatic impairment, although data in severe organ dysfunction are lacking. Dose adjustments are not required based on age or body weight. The introduction of vericiguat into the management of HFrEF represents a meaningful advancement in therapy. While the drug does not significantly extend overall survival, its use is associated with a substantial reduction in the risk of recurrent hospitalizations, which may have important clinical and prognostic implications in this patient population.
- 4 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Open AccessVERICIGUAT: MODERN THERAPY FOR THE TREATMENT OF CHRONIC HEART FAILURE
Vericiguat is the first oral soluble guanylate cyclase (sGC) stimulator developed to reduce the risk of cardiovascular death and heart failure–related hospitalizations in patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF). sGC dysfunction, resulting in impaired synthesis of cyclic guanosine monophosphate (cGMP), may play a keyrole in the pathophysiology of heart failure by affecting myocardial function, vascular tone, and peripheral tissue perfusion. Vericiguat exerts its therapeutic effect by enhancing intracellular cGMP levels, leading to improved cardiac function and vasodilation. Consequently, the drug represents a promising treatment option for patients with HFrEF, particularly those with recent decompensation, requiring intravenous diuretic therapy, or at high risk for rehospitalization due to disease exacerbation. Clinical efficacy of vericiguat was demonstrated in the VICTORIA trial, which enrolled 6,857 patients with HFrEF following recent decompensation. After a median follow-up of 10.8 months, treatment with vericiguat significantly reduced the risk of the composite endpoint of cardiovascular death or heart failure related hospitalization compared with placebo. Patients with more advanced disease also exhibited reductions in NT-proBNP levels, suggesting a potential biomarker of therapeutic response. Vericiguat is generally well tolerated. The most commonly reported adverse events are hypotension and syncope. The drug can be safely administered to patients with mild to moderate renal or hepatic impairment, although data in severe organ dysfunction are lacking. Dose adjustments are not required based on age or body weight. The introduction of vericiguat into the management of HFrEF represents a meaningful advancement in therapy. While the drug does not significantly extend overall survival, its use is associated with a substantial reduction in the risk of recurrent hospitalizations, which may have important clinical and prognostic implications in this patient population.
- Open Access
- 4 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
CRISPR-Cas9 GENE EDITING: MECHANISMS, CLINICAL APPLICATIONS, AND FUTURE PERSPECTIVES
The system of gene editing known as the CRISPR-Cas9 system has revolutionized the field of gene editing and provides a platform that allows for the modification of genetic sequences with precision and efficiency, having implications for both the basic research of science and for treatments. Its mechanism, which is derived from bacterial adaptive immunity, consists of a guide RNA that leads to specific epigenetic DNA sites a nuclease named Cas, to target it for cleavage; this permits gene correction, inactivation, or insertion. The clinical potential of this technology is enormous with applications ranging from hereditary diseases, oncology, and infectious diseases. Of note too, the approvals from the FDA for therapies targeted at the treatment of sickle cell anemia and beta thalassemia speaks volumes to its transformative effect on what was previously in-treatable conditions. In oncology, the technologies are increasing immunotherapies by engineering T-cells and interfering with immune checkpoints, but also working on viral genomes (e.g. HIV, HBV) and destroying antibiotic-resistance genes in bacteria. However, there are still major challenges such as off-target effects, in vivo delivery efficiency and possible immunogenicity of Cas proteins. Future advancements are dedicated to refine the use of the CRP systems using advanced variants such as base and prime editors, and to extend the toolkit by Cas12 and Cas13 for RNA/DNA targeting, as well as devising innovative delivery systems for overcoming the biological barriers. Ethical, regulatory, and societal considerations are paramount in the continued promotion and progressive growth of this technology.
- 4 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Open AccessCRISPR-Cas9 GENE EDITING: MECHANISMS, CLINICAL APPLICATIONS, AND FUTURE PERSPECTIVES
The system of gene editing known as the CRISPR-Cas9 system has revolutionized the field of gene editing and provides a platform that allows for the modification of genetic sequences with precision and efficiency, having implications for both the basic research of science and for treatments. Its mechanism, which is derived from bacterial adaptive immunity, consists of a guide RNA that leads to specific epigenetic DNA sites a nuclease named Cas, to target it for cleavage; this permits gene correction, inactivation, or insertion. The clinical potential of this technology is enormous with applications ranging from hereditary diseases, oncology, and infectious diseases. Of note too, the approvals from the FDA for therapies targeted at the treatment of sickle cell anemia and beta thalassemia speaks volumes to its transformative effect on what was previously in-treatable conditions. In oncology, the technologies are increasing immunotherapies by engineering T-cells and interfering with immune checkpoints, but also working on viral genomes (e.g. HIV, HBV) and destroying antibiotic-resistance genes in bacteria. However, there are still major challenges such as off-target effects, in vivo delivery efficiency and possible immunogenicity of Cas proteins. Future advancements are dedicated to refine the use of the CRP systems using advanced variants such as base and prime editors, and to extend the toolkit by Cas12 and Cas13 for RNA/DNA targeting, as well as devising innovative delivery systems for overcoming the biological barriers. Ethical, regulatory, and societal considerations are paramount in the continued promotion and progressive growth of this technology.
- Open Access
- 2 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
NO-REFLOW PHENOMENON – MECHANISM, PREVENTION AND TREATMENT STRATEGIES
No-reflow phenomenon is a major clinical problem in the treatment of acute myocardial infarction, which happens despite effective recanalization of the epicardial coronary arteries. It is also marked by compromised microvascular blood circulation and it is linked to poor clinical outcome, such as bigger infarct size, left ventricular remodeling and higher mortality rates. The lack of no-reflow pathophysiology is multifactorial in nature and consists of distal microthromboembolization, reperfusion injury, endothelial dysfunction, microvascular spasm, and excessive inflammatory response. The no-reflow diagnosis continues to be difficult. Angiographic techniques such as Thrombolysis In Myocardial Infarction (TIMI) flow grade, which are used widely, are not very effective in evaluating microvascular perfusion. Higher resolution imaging including cardiac magnetic resonance imaging, myocardial contrast echocardiography, among others, offer a more accurate analysis; nevertheless, their application in clinical practice is limited due to their infrequent availability and high cost. No-reflow phenomenon is also a complicated combating mechanism. The existing approaches to therapy are mainly directed at alleviating the burden of thrombus, limiting the area of infarction, and alleviating reperfusion damages. However, the efficacy of these methods is dynamic and inadequately frequently, and no single therapy aimed at the coronary microvascular dysfunction development is determined. This means that more investigations about the mechanism behind no-reflow, the creation of more sensitive diagnostic techniques, and specific treatment of no-reflow have to be taken to enhance microvascular reperfusion and patient outcome.
- 2 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Open AccessNO-REFLOW PHENOMENON – MECHANISM, PREVENTION AND TREATMENT STRATEGIES
No-reflow phenomenon is a major clinical problem in the treatment of acute myocardial infarction, which happens despite effective recanalization of the epicardial coronary arteries. It is also marked by compromised microvascular blood circulation and it is linked to poor clinical outcome, such as bigger infarct size, left ventricular remodeling and higher mortality rates. The lack of no-reflow pathophysiology is multifactorial in nature and consists of distal microthromboembolization, reperfusion injury, endothelial dysfunction, microvascular spasm, and excessive inflammatory response. The no-reflow diagnosis continues to be difficult. Angiographic techniques such as Thrombolysis In Myocardial Infarction (TIMI) flow grade, which are used widely, are not very effective in evaluating microvascular perfusion. Higher resolution imaging including cardiac magnetic resonance imaging, myocardial contrast echocardiography, among others, offer a more accurate analysis; nevertheless, their application in clinical practice is limited due to their infrequent availability and high cost. No-reflow phenomenon is also a complicated combating mechanism. The existing approaches to therapy are mainly directed at alleviating the burden of thrombus, limiting the area of infarction, and alleviating reperfusion damages. However, the efficacy of these methods is dynamic and inadequately frequently, and no single therapy aimed at the coronary microvascular dysfunction development is determined. This means that more investigations about the mechanism behind no-reflow, the creation of more sensitive diagnostic techniques, and specific treatment of no-reflow have to be taken to enhance microvascular reperfusion and patient outcome.
- Open Access
- 30 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
USE OF VERCIGUAT IN THE TREATMENT OF HEART FAILURE
Heart failure remains a major challenge in contemporary cardiology, characterized by high morbidity, frequent hospitalizations, and an unfavorable prognosis despite substantial advances in guideline-directed therapy. Although modern multidrug treatment has improved clinical outcomes, a considerable proportion of patients continue to experience disease progression and recurrent exacerbations, particularly in high-risk populations. Vericiguat is a novel oral agent used in the treatment of heart failure and represents an adjunct to standard therapy in selected patients. To date, clinical studies have evaluated the efficacy and safety of vericiguat in patients with both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. Available evidence suggests that the clinical effects of vericiguat vary depending on the heart failure phenotype and the clinical context, including disease stability and the risk of further deterioration. This paper provides a comprehensive review of current data on the use of vericiguat across different heart failure phenotypes, with particular emphasis on clinical trial outcomes, therapeutic efficacy, and safety profile. The limitations of existing evidence are discussed, along with the potential role of vericiguat within contemporary treatment strategies. Overall, current findings indicate that vericiguat should not be regarded as a universal therapy for all patients with heart failure, but rather as a complementary treatment option for carefully selected individuals, in whom additional therapeutic strategies may be required.
- 30 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
Open AccessUSE OF VERCIGUAT IN THE TREATMENT OF HEART FAILURE
Heart failure remains a major challenge in contemporary cardiology, characterized by high morbidity, frequent hospitalizations, and an unfavorable prognosis despite substantial advances in guideline-directed therapy. Although modern multidrug treatment has improved clinical outcomes, a considerable proportion of patients continue to experience disease progression and recurrent exacerbations, particularly in high-risk populations. Vericiguat is a novel oral agent used in the treatment of heart failure and represents an adjunct to standard therapy in selected patients. To date, clinical studies have evaluated the efficacy and safety of vericiguat in patients with both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. Available evidence suggests that the clinical effects of vericiguat vary depending on the heart failure phenotype and the clinical context, including disease stability and the risk of further deterioration. This paper provides a comprehensive review of current data on the use of vericiguat across different heart failure phenotypes, with particular emphasis on clinical trial outcomes, therapeutic efficacy, and safety profile. The limitations of existing evidence are discussed, along with the potential role of vericiguat within contemporary treatment strategies. Overall, current findings indicate that vericiguat should not be regarded as a universal therapy for all patients with heart failure, but rather as a complementary treatment option for carefully selected individuals, in whom additional therapeutic strategies may be required.
- Open Access
- 23 March 2026
- Published by National Institute of Public Health NIH (National Research Institute) in Przeglad Epidemiologiczny
- Vol. 80 (1) , 116-132
Air pollution and cardiovascular disease: A review of current scientific data
Introduction and Aim Air pollution is a major public health concern, adversely affecting both the respiratory and cardiovascular systems. The main pollutants include particulate matter (PM2.5, PM10), nitrogen oxides (NO2), tropospheric ozone (O3), carbon monoxide (CO), sulfur dioxide (SO2), and other toxic compounds. Numerous studies confirm an association between exposure to these pollutants and increased incidence of cardiovascular diseases, including ischemic heart disease, stroke, arrhythmias, and heart failure. This paper aims to summarise current knowledge on the effects of air pollution on the cardiovascular system and to discuss underlying pathophysiological mechanisms. State of Knowledge Air pollution is one of the leading environmental risk factors for premature mortality worldwide. The most harmful components include fine particulate matter (PM2.5), nitrogen oxides (NO2), ozone (O3), carbon monoxide (CO), and sulfur dioxide (SO₂). In 2021, the World Health Organisation (WHO) revised its air quality guidelines, lowering the recommended annual PM2.5 limit to 5 µg/m3. Pollutants induce oxidative stress, inflammation, endothelial dysfunction, and autonomic imbalance, contributing to cardiovascular disease development and progression. Short-term exposure increases the risk of acute events such as myocardial infarction and arrhythmias, while long-term exposure promotes atherosclerosis and chronic heart failure. The elderly, children, and individuals with chronic diseases are particularly vulnerable. This issue remains a major public health challenge globally. Summary Air pollution is a key risk factor for cardiovascular disease. Reducing exposure through continuous air quality monitoring and effective preventive measures is essential for protecting public health.
- 23 March 2026
- Published by National Institute of Public Health NIH (National Research Institute) in Przeglad Epidemiologiczny
- Vol. 80 (1) , 116-132
Open AccessAir pollution and cardiovascular disease: A review of current scientific data
Introduction and Aim Air pollution is a major public health concern, adversely affecting both the respiratory and cardiovascular systems. The main pollutants include particulate matter (PM2.5, PM10), nitrogen oxides (NO2), tropospheric ozone (O3), carbon monoxide (CO), sulfur dioxide (SO2), and other toxic compounds. Numerous studies confirm an association between exposure to these pollutants and increased incidence of cardiovascular diseases, including ischemic heart disease, stroke, arrhythmias, and heart failure. This paper aims to summarise current knowledge on the effects of air pollution on the cardiovascular system and to discuss underlying pathophysiological mechanisms. State of Knowledge Air pollution is one of the leading environmental risk factors for premature mortality worldwide. The most harmful components include fine particulate matter (PM2.5), nitrogen oxides (NO2), ozone (O3), carbon monoxide (CO), and sulfur dioxide (SO₂). In 2021, the World Health Organisation (WHO) revised its air quality guidelines, lowering the recommended annual PM2.5 limit to 5 µg/m3. Pollutants induce oxidative stress, inflammation, endothelial dysfunction, and autonomic imbalance, contributing to cardiovascular disease development and progression. Short-term exposure increases the risk of acute events such as myocardial infarction and arrhythmias, while long-term exposure promotes atherosclerosis and chronic heart failure. The elderly, children, and individuals with chronic diseases are particularly vulnerable. This issue remains a major public health challenge globally. Summary Air pollution is a key risk factor for cardiovascular disease. Reducing exposure through continuous air quality monitoring and effective preventive measures is essential for protecting public health.